Loading
CAR-T Cell Therapy Research · Journal article
Clinical Cancer Research · August 17, 2026
Encouraging direction, but not yet definitive.
This prospective biomarker study identified baseline circulating and intratumoral γδ T cells, and early CD8⁺PD-1⁺ expansion, as predictors of improved progression-free and overall survival in HCC patients receiving first-line atezolizumab-bevacizumab. The findings were partially validated in external trial and immunotherapy-treated colorectal cancer cohorts, suggesting potential utility for patient stratification, though the small primary cohort and lack of prospective validation in a randomized design limit current clinical application.
Prospective single-arm biomarker study with external validation in randomized trial and registry cohorts. HCC patients treated with first-line atezolizumab-bevacizumab (primary: 87% male, median age 65 years, 65% BCLC-C stage); external populations from randomized trials and registry cohorts.. Intervention: First-line atezolizumab-bevacizumab. Compared with: In external cohorts: sorafenib for HCC; immunotherapy for MSI-H CRC; no concurrent control in primary prospective study. n = 31.
High baseline circulating γδ T cells associated with disease control (p=0.006) and longer PFS (p=0.02) High intratumoral γδ T-cell signature associated with higher response (p<0.01), longer PFS (p<0.001), and longer OS (p=0.003) in AtezoBev-treated patients, not sorafenib Increase in circulating CD8⁺PD-1⁺ cells correlated with longer PFS (p=0.03); CD8⁺TIGIT⁺ increase associated with shorter PFS (p=0.04)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If prospectively validated, these biomarkers could enable early identification of HCC patients likely to benefit from atezolizumab-bevacizumab and guide treatment selection. Current evidence is insufficient to recommend routine clinical use without further confirmation in a prospective randomized biomarker validation trial.
A prospective single-arm biomarker study in 31 HCC patients with supportive validation in external trial cohorts, identifying immune predictors of AtezoBev response via rigorous multimodal immunophenotyping, but limited by small primary cohort and surrogate endpoints.
As stated by the source record.
Quoted from the source exactly as published.
If prospectively validated, these biomarkers could enable early identification of HCC patients likely to benefit from atezolizumab-bevacizumab and guide treatment selection. Current evidence is insufficient to recommend routine clinical use without further confirmation in a prospective randomized biomarker validation trial.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: We aimed to identify circulating and tumor immune features predictive of oncological outcomes under Atezolizumab-Bevacizumab (AtezoBev) therapy for hepatocellular carcinoma (HCC). METHODS: We conducted a prospective study in 31 patients treated with first-line AtezoBev, integrating sequential PBMC immunophenotyping, cytokine profiling and whole-blood RNA sequencing. Tumor RNA-sequencing data from clinical trial (GO30140/IMbrave150, 209 AtezoBev and 58 sorafenib-treated patients), together with 163 MSI-H colorectal cancer (CRC) treated by immunotherapy were used to assess the predictive value of immune signatures. RESULTS: Based on PBMC analysis at baseline (87% of male, age 65 years and 65% of BCLC-C), high baseline circulating γδ T-cells was associated with disease control (p=0.006) and longer progression free survival (PFS) (p=0.02). In tumor RNA-seq, a high intratumoral γδ T signature was also associated with higher response (p<0.01), longer PFS (p<0.001), and longer overall survival (p=0.003) exclusively in AtezoBev-treated patients, but not for those treated by sorafenib. In MSI-H CRC treated by immunotherapy, a high γδ T-cell signature was associated with longer PFS (p=0.034). An increase in circulating CD8⁺TIGIT⁺ cells was associated with shorter PFS (p=0.04), whereas an increase in CD8⁺PD-1⁺ cells correlated with longer PFS (p=0.03). Paired transcriptomic analyses confirmed an early induction of T cell-associated interferon-γ signaling at 3 weeks after the first injection of AtezoBev in patients that experienced response. CONCLUSIONS: High baseline circulating and tumor γδ T cells and early circulating CD8⁺PD-1⁺ T Cell expansion were associated with better outcome under AtezoBev. Early increase in circulating CD8⁺TIGIT⁺ cells was associated with treatment resistance.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.